Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award.
"GHP Magazine's Biotechnology Awards 2024” are...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for...
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie (MEIE), the National Research Council of Canada...
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et de l’Énergie (MEIE) du Québec and the...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment...
Montreal / July 4, 2022
NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event...